

## Inhibitory Effects of Naturally Occurring Flavonoids on Rat Lens Aldose Reductase

Sang Hoon Jung<sup>1,2</sup>, Sam Sik Kang<sup>1</sup>, Kuk Hyun Shin<sup>1</sup>, and Yeong Shik Kim<sup>1,\*</sup>

<sup>1</sup>Natural Products Research Institute, College of Pharmacy, Seoul National University, Seoul 151-747, Korea

<sup>2</sup>Natural Products Research Center, Korea Institute of Science and Technology, Seoul 136-791, Korea

**Abstract** – Aldose reductase (AR), the key enzyme of the polyol pathway, is known to play important roles in the diabetic complications. The inhibitors of AR, therefore, would be potential agents for the prevention of diabetic complications. In order to clarify the structural requirements of flavonoids for aldose reductase inhibitory activity, thirty flavonoids were examined. Among the thirty flavonoids, flavonols such as quercetin (**5**), reyneutrins (**7**), quercitrin (**9**), isoquercitrin (**11**), and avicularin (**14**) were found to exhibit much stronger AR inhibition. Lonicerin (**10**), amentoflavone (**27**) and sophoraflavanone B (**30**) were also showed strong inhibitory activity. Especially, quercitrin and reyneutrins exhibited the most inhibitory potency on rat lens (RL) AR. The results suggested that flavonol having the 7-hydroxyl and/or catechol moiety at the B ring exhibit strong activity. In addition, flavonols having 3-*O*-monosaccharide also showed stronger inhibition than free flavonols at the 3-position. These results suggested that quercitrin and reyneutrins are attributed to be the promising compounds for the prevention and/or treatment of diabetic complications.

**Keywords** – Aldose reductase, Quercitrin, Reyneutrins, Diabetic complications

### Introduction

Aldose reductase (AR), the key enzyme in the polyol pathway, has been demonstrated to play important roles not only in the cataract formation in the lens (Van Heyningen, 1959), but also in the pathogenesis of diabetic complications such as neuropathy (Ward, 1973), nephropathy (Beyer-Mears *et al.*, 1984) and retinopathy (Engerman and Kern, 1984). Evidence suggests that compounds that inhibit AR could be effective for the prevention of diabetic complications. A number of structurally diverse naturally occurring and synthetic AR inhibitors have been studied *in vivo* to clarify their effectiveness for prevention of diabetic complications in clinical trials (Handelsman and Turtle, 1981) as well as experimental animals (Beyer-Mears and Cruz, 1985). Since the mid Seventies, several studies on the inhibition of aldose reductase by flavonoids have been reported, and Matsuda *et al.* reported structure-activity relationship of flavonoids and related compounds for aldose reductase inhibitory activity (Matsuda *et al.*, 2002).

In a series of investigations to evaluate potential AR inhibitors from the Korean plants, we have shown that

some hot water and methanol extracts from natural products exhibited a significant inhibition of bovine lens (BL) or RLAR *in vitro* (Shin *et al.*, 1993; Jung *et al.*, 2003), and a number of flavonoid compounds were isolated and characterized as AR inhibitors from plants (Shin *et al.*, 1994; 1995; Jung *et al.*, 2002).

In a previous paper, we synthesized flavonoid derivatives and their inhibitory effects on RLAR, platelet aggregation and antioxidant effects have been tested. Some chalcone derivatives were found to possess AR inhibition and antioxidant activities *in vitro* as well as inhibition in the accumulation of sorbitol *in vivo*, in which 3,4,2',4'-tetrahydroxychalcone (butein) was the most promising compound for the prevention or treatment of diabetic complications (Lim *et al.*, 2000; 2001).

In the present study, naturally occurring flavonoids were examined to clarify the further structural requirements of flavonoids for aldose reductase inhibitory activity

### Experimental

**Flavonoids** – Tested flavonoids were provided by Prof. Dr. Sam Sik Kang (Natural Products Research Institute, Seoul National University).

**Preparation of RLAR** – Crude RLAR was prepared

\*Author for correspondence

Fax: +82-2-765-4768, E-mail: kims@plaza.snu.ac.kr

as follows: rat lenses were removed from Sprague-Dawley rats weighing 250~280 g and frozen until use. The supernatant fraction of the rat lens homogenate was prepared according to Hayman and Kinoshita (1965), and then partially purified according to Inagaki *et al.* (1982). The partially purified enzyme with a specific activity of 6.5 mU/mg was routinely used to test enzyme inhibition. The partially purified material was separated into 1.0 ml aliquots and stored at  $-40^{\circ}\text{C}$ .

**Measurement of RLAR activity** – RLAR activities were assayed spectrophotometrically by measuring the decrease in absorption of NADPH at 340 nm over a 4 min period with DL-glyceraldehyde as a substrate (Sato and Kador, 1990). Each 1.0 ml cuvette contained equal units of enzyme, 0.10 M sodium phosphate buffer (pH 6.2), 0.3 mM NADPH with or without 10 mM substrate and inhibitor.


The concentration of inhibitors giving 50% inhibition of enzyme activity ( $\text{IC}_{50}$ ) was calculated from the least-squares regression line of the logarithmic concentrations plotted against the residual activity.

## Results and Discussion

The chemical structures of the naturally occurring flavonoid derivatives tested are listed in Table 1. Their inhibitory effects of 18 flavonols, 5 flavones and 7 other flavonoids on RLAR using DL-glyceraldehyde as a substrate are shown in Table 2.


Flavonols such as quercetin (5), reynetrin (7), quercitrin (9), isoquercitrin (11), and avicularin (14) were found to exhibit much stronger AR inhibition (more than 85% inhibition at 5  $\mu\text{g}/\text{ml}$ ) than other flavonoids. Lonicerin (10),

**Table 1.** Chemical structure of tested flavonoids on RLAR




	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	R <sub>4</sub>	R <sub>5</sub>	R <sub>6</sub>	R <sub>7</sub>
Anhydrocaritin-3- <i>O</i> -Rha (1)	<i>O</i> -Rha	H	OCH <sub>3</sub>	H	H	OH	Pre
Kaempferol-3- <i>O</i> -Glc-(1 → 2)-Rha (2)	<i>O</i> -Glc-(1 → 2)-Rha	H	OH	H	H	OH	H
Icariin (3)	<i>O</i> -Rha	H	OCH <sub>3</sub>	H	H	<i>O</i> -Glc	Pre
Quercetin (5)	OH	OH	OH	H	H	OH	H
Populin (6)	OH	H	OH	H	H	<i>O</i> -Glc	H
Reynetrin (7)	<i>O</i> -Xyl	OH	OH	H	H	OH	H
Linarin (8)	H	H	OCH <sub>3</sub>	H	H	<i>O</i> -Rut	H
Quercitrin (9)	<i>O</i> -Rha	OH	OH	H	H	OH	H
Lonicerin (10)	H	OH	OH	H	H	<i>O</i> -Neo	H
Isoquercitrin (11)	<i>O</i> -Glc	OH	OH	H	H	OH	H
Quercetin 3,3'-dimethyl ether (12)	OCH <sub>3</sub>	OCH <sub>3</sub>	OH	H	H	OH	H
6,5'-Diprenylquercetin (13)	OH	OH	OH	Pre	Pre	OH	H
Avicularin (14)	<i>O</i> -Ara( <i>f</i> )	OH	OH	H	H	OH	H
Laricitrin-3- <i>O</i> -Rut (15)	<i>O</i> -Rut	OCH <sub>3</sub>	OH	OH	H	OH	H
Isorhamnetin-3- <i>O</i> -Rut (16)	<i>O</i> -Rut	OCH <sub>3</sub>	OH	H	H	OH	H
Diosmetin-7- <i>O</i> -glucoside (17)	H	OH	OCH <sub>3</sub>	H	H	<i>O</i> -Glc	H
Kaempferol-3- <i>O</i> -Rut (20)	<i>O</i> -Rut	H	OH	H	H	OH	H
3,3'-Dimethylquercetin 4'- <i>O</i> -Glc (21)	OCH <sub>3</sub>	OCH <sub>3</sub>	<i>O</i> -Glc	H	H	OH	H
Kaempferol-3- <i>O</i> -(6"- <i>O</i> - <i>p</i> -coumaroyl-Glc-(1 → 2)-Rha (22)	<i>O</i> -(6"- <i>O</i> - <i>p</i> -coumaroyl-Glc-(1 → 2)-Rha	H	OH	H	H	OH	H
Jaceosidin (23)	H	OCH <sub>3</sub>	OH	H	OCH <sub>3</sub>	OH	H
Isorhamnetin (25)	OH	OCH <sub>3</sub>	OH	H	H	OH	H
Anhydrocaritin (26)	OH	H	OCH <sub>3</sub>	H	H	OH	Pre
Diosmin (29)	H	OH	OCH <sub>3</sub>	H	H	<i>O</i> -Rut	H


Glc:  $\beta$ -D-glucopyranosyl; Rha:  $\alpha$ -L-rhamnopyranosyl; Xyl:  $\beta$ -D-Xylopyranosyl; Ara:  $\alpha$ -L-arabinopyranosyl; Ara(*f*):  $\alpha$ -L-arabinofuranosyl; Rut: rutinosyl; Neo: neohesperidosyl; Pre: prenyl




Kenusanone A (4)




Echinoisophoranone (18)




Isosophoranone (19)




Maackiain (24)



Amentoflavone (27)



Echinoisoflavanone (28)



Sophoraflavanone B (30)

amentoflavone (27) and sophoraflavanone B (30) also showed strong inhibitory activities.

To evaluate the AR inhibitory activities between active flavonoids more precisely, their inhibitory potencies and

IC<sub>50</sub> values were estimated and indicated in Table 2.

Although slightly less potent than epalrestat (ONO Co.), known as one of typical AR inhibitors (IC<sub>50</sub> value, 0.082 × 10<sup>-6</sup> M), the inhibitory potencies of quercitrin and reynoutrin

**Table 2.** Inhibitory effect of flavonoids on RLAR

Flavonoids	Inhibition % <sup>b)</sup>	IC <sub>50</sub> values (µg/ml)	Micromolar IC <sub>50</sub> values of active flavonoids (µM)
TMG <sup>a)</sup>	92.3	–	1.99
Epalrestat	99.9	–	0.082
1	68.1	2.25	–
2	36.4	> 5	–
3	19.4	> 5	–
4	28.7	> 5	–
5	87.4	0.49	1.62
6	78.0	1.57	–
7	91.9	0.12	0.27
8	20.4	> 5	–
9	99.6	0.072	0.15
10	90.1	0.31	0.52
11	83.1	0.80	1.72
12	82.6	1.34	–
13	68.0	2.15	–
14	91.8	0.60	1.38
15	55.0	> 5	–
16	72.6	2.07	–
17	35.1	> 5	–
18	8.0	> 5	–
19	15.2	> 5	–
20	70.7	2.76	–
21	52.1	> 5	–
22	67.5	3.05	–
23	42.8	> 5	–
24	29.1	> 5	–
25	69.0	2.95	–
26	17.1	> 5	–
27	93.4	1.34	–
28	39.7	> 5	–
29	66.1	2.43	–
30	94.9	0.24	0.71

<sup>a)</sup>Tetramethyleneglutaric acid.

<sup>b)</sup>Each sample concentration was 5 µg/ml.

as expressed by IC<sub>50</sub> values, were  $0.15 \times 10^{-6}$  M and  $0.27 \times 10^{-6}$  M, respectively.

Varma and Kinoshita (1976) have indicated some possible relationships of structure to the inhibiting potencies of flavones. The hydroxylation in the 4'-position has beneficial effects, and the abolition of the double bond between C-2 and C-3 leads to a decrease of inhibition. In support of these findings, the 4'-hydroxyl group (R<sub>3</sub> position of flavonoid in Table 1) of tested compounds was important for showing the inhibition of AR activity than the methoxy group at the same position. The double bond of C-2,3 was also important in enhancing the activity.

Our previous study demonstrated that some synthetic chalcone derivatives were found to possess AR inhibition *in vitro* as well as inhibition in the accumulation of

sorbitol *in vivo*. We postulated the possible relationships of structure to the inhibitory activities of flavonoids: 1) 4'-hydroxyl at the B ring show stronger activity; 2) chalcones having catechol moiety at the B ring (the 3,4-ortho-dihydroxyl moiety) show stronger activity; 3) chalcone shows a stronger activity than dihydrochalcone, in which 3,4,2',4'-tetrahydroxychalcone was the most potent inhibitor for aldose reductase (Lim *et al.*, 2000). In the present study, our results indicated that ring-closure form (quercetin-like structure) of 3,4,2',4'-tetrahydroxychalcone exhibit stronger activities than other flavonoids. Flavonols having 3-O-monosaccharide (quercitrin) also showed stronger inhibition than free flavonols at the 3-position (quercetin).

In conclusion, from *in vitro* data, quercitrin and reyneutrins were found to show potent inhibitory activities, therefore, these flavonoids could be offered as leading compounds for further study as a new drug for diabetic complications.

### Acknowledgements

This work was supported by the grant from the Korea Health 21 R&D Project, Ministry of Health & Welfare, Republic of Korea (HMP-01-PJ2-PG6-01NA01-002). The authors are grateful to the ONO Co. in Japan and Prof. K. Ohuchi in Tohoku Univ. for providing the standard material, epalrestat.

### References

- Beyer-Mears, A., Ku, L., and Cohen, M., Glomerular polyol accumulation in diabetes and its prevention by oral sorbinil. *Diabetes* 33, 604-607 (1984).
- Beyer-Mears, A., and Cruz, E., Reversal of diabetic cataract by sorbinil, an aldose reductase inhibitor. *Diabetes* 34, 15-21 (1985).
- Engerman, R.L., and Kem, T.S., Experimental galactosemia produces diabetic-like retinopathy. *Diabetes* 33, 97-100 (1984).
- Handelsman, D.J., and Turtle, J.R., Clinical trial of an aldose reductase inhibitor in diabetic neuropathy. *Diabetes* 30, 459-64 (1981).
- Hayman, S., and Kinoshita, J.H., Isolation and properties of lens aldose reductase. *J. Biol. Chem.* 240, 877-882 (1965).
- Inagaki, K., Miwa, I., and Okuda, J., Affinity purification and glucose specificity of aldose reductase from bovine lens. *Arch. Biochem. Biophys.* 216, 337-344 (1982).
- Jung, S.H., Lee, Y.S., Lee, S., Lim, S.S., Kim, Y.S., and Shin, K.H., Isoflavonoids from the rhizomes of *Belamcanda chinensis* and their effects on aldose reductase and sorbitol accumulation in streptozotocin induced diabetic rat tissues. *Arch. Pharm. Res.* 25, 306-312 (2002).
- Jung, S.H., Lim, S.S., Lee, S., Lee, Y.S., Shin, K.H., and Kim, Y.S., Aldose Reductase Inhibitory Activity of Methanol

- Extracts from the Korean Plants. *Nat. Prod. Sci.* 9, 34-37 (2003).
- Lim, S.S., Jung, S.H., Ji, J., Shin, K.H., and Keum, S.R. Synthesis of flavonoids and their effects on aldose reductase and sorbitol accumulation in streptozotocin-induced diabetic rat tissues. *J. Pharm. Pharmacol.* 53, 653-668 (2001).
- Lim, S.S., Jung, S.H., Ji, J., Shin, K.H., and Keum, S.R. Inhibitory effects of 2'-hydroxychalcones on rat lens aldose reductase and rat platelet aggregation. *Chem. Pharm. Bull.* 48, 1786-1789 (2000).
- Masuda, H., Morikawa, T., Toguchida, I., and Yoshikawa, M. Structural requirements of flavonoids and related compounds for aldose reductase inhibitory activity. *Chem. Pharm. Bull.* 50, 788-795 (2002).
- Sato, S., and Kador, P.F., Inhibition of aldehyde reductase by aldose reductase inhibitors. *Biochem. Pharmacol.* 40, 1033-1042 (1990).
- Shin, K.H., Chung, M.S., Chae, Y.J., Yoon, K.Y., and Cho, T.S., A survey for aldose reductase inhibition of some herbal medicines. *Fitoterapia* 14, 130-133 (1993).
- Shin, K.H., Kang, S.S., Kim, H.J., and Shin, S.W., Isolation of an aldose reductase inhibitor from the fruits of *Vitex rotundifolia*. *Phytomed.* 1, 145-147 (1994).
- Shin, K.H., Kang, S.S., Seo, E.A., and Shin, S.W., Isolation of aldose reductase inhibitors from the flowers of *Chrysanthemum boreale*. *Arch. Pharm. Res.* 18, 65-68 (1995).
- Van Heyningen, R., Formation of polyol by the lens of the rat with sugar cataract. *Nature* 184, 194-196 (1959).
- Varma, S.D., and Kinoshita, J.H. Inhibition of lens aldose reductase by flavonoids-their possible role in the prevention of diabetic cataracts. *Biochem. Pharmacol.* 25, 2505-2513 (1976).
- Ward, J.D., The polyol pathway in the neuropathy of early diabetes. In "Advance in Metabolic Disorders (Suppl. 2)" Ed. By R. A. Camerini-Davalos and H. S. Cole, Academic Press, New York, p. 425 (1973).

(Accepted January 10, 2004)